Stem definition | Drug id | CAS RN |
---|---|---|
1557 | 61-90-5 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
None | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Foetal growth restriction | 87.67 | 63.59 | 15 | 127 | 7538 | 63481342 |
None
None
None
Source | Code | Description |
---|---|---|
CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
CHEBI has role | CHEBI:75772 | S. cerevisiae metabolites |
CHEBI has role | CHEBI:76924 | plant metabolites |
CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
CHEBI has role | CHEBI:84735 | algal metabolites |
CHEBI has role | CHEBI:83056 | Daphnia magna metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Classical phenylketonuria | contraindication | 7573000 | |
Poisoning by digitalis glycoside | contraindication | 12876009 | |
Sarcoidosis | contraindication | 31541009 | DOID:11335 |
End stage renal disease | contraindication | 46177005 | DOID:784 |
Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
Heart disease | contraindication | 56265001 | DOID:114 |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Ventricular fibrillation | contraindication | 71908006 | |
Hypercalciuria | contraindication | 71938000 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Kidney stone | contraindication | 95570007 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.5 | acidic |
pKa2 | 9.88 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Large neutral amino acids transporter small subunit 1 | Transporter | IC50 | 4.07 | CHEMBL |
ID | Source |
---|---|
4018684 | VUID |
N0000146995 | NUI |
D00030 | KEGG_DRUG |
4018684 | VANDF |
C0023401 | UMLSCUI |
CHEBI:25017 | CHEBI |
LEU | PDB_CHEM_ID |
CHEMBL291962 | ChEMBL_ID |
6106 | PUBCHEM_CID |
DB00149 | DRUGBANK_ID |
D007930 | MESH_DESCRIPTOR_UI |
6165 | INN_ID |
3312 | IUPHAR_LIGAND_ID |
GMW67QNF9C | UNII |
6308 | RXNORM |
40035 | MMSL |
NOCODE | MMSL |
005060 | NDDF |
412424004 | SNOMEDCT_US |
83797003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
ProcalAmine | HUMAN PRESCRIPTION DRUG LABEL | 22 | 0264-1915 | INJECTION | 0.27 g | INTRAVENOUS | NDA | 24 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 1.40 g | INTRAVENOUS | NDA | 23 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 1.40 g | INTRAVENOUS | NDA | 23 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 1.40 g | INTRAVENOUS | NDA | 23 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-3200 | SOLUTION | 1.04 g | INTRAVENOUS | ANDA | 20 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-3205 | SOLUTION | 1.04 g | INTRAVENOUS | ANDA | 20 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-4500 | SOLUTION | 1.04 g | INTRAVENOUS | ANDA | 20 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-4500 | SOLUTION | 1.04 g | INTRAVENOUS | ANDA | 20 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-4500 | SOLUTION | 1.04 g | INTRAVENOUS | ANDA | 20 sections |
FreAmine III | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9010 | INJECTION, SOLUTION | 0.91 g | INTRAVENOUS | NDA | 24 sections |
FreAmine III | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9011 | INJECTION, SOLUTION | 0.91 g | INTRAVENOUS | NDA | 24 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9341 | SOLUTION | 1.40 g | INTRAVENOUS | NDA | 23 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9361 | SOLUTION | 0.84 g | INTRAVENOUS | NDA | 23 sections |
HepatAmine | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9371 | INJECTION, SOLUTION | 1.10 g | INTRAVENOUS | NDA | 23 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0180 | INJECTION | 584 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0180 | INJECTION | 584 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0184 | INJECTION, EMULSION | 584 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0184 | INJECTION, EMULSION | 584 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0188 | INJECTION | 584 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0188 | INJECTION | 584 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0194 | INJECTION | 584 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0194 | INJECTION | 584 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0198 | INJECTION | 438 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0198 | INJECTION | 438 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0202 | INJECTION | 584 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0202 | INJECTION | 584 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0202 | INJECTION | 584 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0206 | INJECTION | 584 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0206 | INJECTION | 584 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0206 | INJECTION | 584 mg | INTRAVENOUS | NDA | 20 sections |